Navigation Links
A Broad-Spectrum Antibiotic with Activity Against MRSA and Pseudomonas Aeruginosa Would Earn a Higher Patient Share in the U.S. than in Europe for the Treatment of Hospital-Acquired Pneumonia
Date:3/3/2009

Merck's Drug Will Remain Decision Resources Gold Standard Through 2017, According to a New Report from Decision Resources

WALTHAM, Mass., March 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a broad-spectrum intravenous antibiotic that has activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), shows higher efficacy than the current benchmark (Wyeth's Zosyn/Tazocin) and is priced 50 percent higher than Zosyn/Tazocin would earn a higher patient share in the U.S. (50 percent) than in Europe (30 percent) for the treatment of hospital-acquired pneumonia. This is due to infectious disease specialists in Europe being more sensitive to pricing in their prescribing decisions.

The new report entitled Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics also finds that Merck's Primaxin will remain Decision Resources' proprietary clinical gold standard through 2017. While some therapies in development for hospital-acquired pneumonia hold promise, most have efficacy, safety and tolerability and/or delivery issues when compared to Primaxin.

"Interviewed thought leaders believe that Primaxin has a better spectrum of activity than the benchmark therapy, Zosyn/Tazocin and perceive the agent to be more active against ESBL-producing E. coli and Klebsiella pneumoniae, Pseudomonas and Acinetobacter," stated Hemali Patel, Ph.D., analyst at Decision Resources. "Prescribers we surveyed agree that Primaxin is the most effective antibiotic for hospital-acquired pneumonia."

About the Report

Hospital-Acquired Pneumonia: Resistance Concerns Create Opportunities for New Broad-Spectrum Antibiotics is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Antibiotic Combo Fights Resistant TB
2. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
3. Antibiotic-Resistant Meningitis Reported in U.S.
4. Health experts urge supermarket pharmacies to get smart about free antibiotics
5. Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
6. Could carbon dioxide replace antibiotics in surgery?
7. Study shows rise in antibiotic resistant pediatric head and neck infections
8. Free antibiotics: The wrong prescription for cold and flu season
9. E. coli persists against antibiotics through HipA-induced dormancy
10. Antibiotics as Loss Leaders?
11. Preventive Use of Antibiotics Cuts ICU Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... International Protein, ... nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in Hilton ... and nutritional scientist who was determined to create a line of products that would ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... 19, 2017 , ... Next week after January 20th, the fear for many ... that circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis ... government public servants were suppose to prioritize. Interviews provided below. , Among ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
Breaking Medicine Technology: